Johnson & Johnson's single-dose COVID-19 vaccine effective, safe: FDA
The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilised variant of the SARS-CoV-2 S protein.
- Feb 24, 2021,
- Updated Feb 24, 2021 10:31 PM IST
Drug maker Johnson & Johnson's single-shot COVID-19 vaccine is safe and effective as per the data submitted from its ongoing multi-national Phase 3 randomised, double-blind and placebo-controlled trials, a briefing document published by the US Food and Drug Administration (FDA) said.
Johnson & Johnson had sought emergency use authorisation for its vaccine on February 4. FDA's advisory committee for approving the vaccine will meet on Friday to take a decision on the issue.
The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilised variant of the SARS-CoV-2 S protein.
More COVID-19 vaccines on the way; Serum, Dr Reddy's, Biological E in advanced stages
Drug maker Johnson & Johnson's single-shot COVID-19 vaccine is safe and effective as per the data submitted from its ongoing multi-national Phase 3 randomised, double-blind and placebo-controlled trials, a briefing document published by the US Food and Drug Administration (FDA) said.
Johnson & Johnson had sought emergency use authorisation for its vaccine on February 4. FDA's advisory committee for approving the vaccine will meet on Friday to take a decision on the issue.
The vaccine, known as Ad26.COV2.S, is a replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding a stabilised variant of the SARS-CoV-2 S protein.
More COVID-19 vaccines on the way; Serum, Dr Reddy's, Biological E in advanced stages